Outcomes of cataract surgery in patients with neovascular age-related macular degeneration in the era of anti-vascular endothelial growth factor therapy

Homayoun Tabandeh, Nauman A. Chaudhry, David S. Boyer, Veronica A. Kon-Jara, Harry W Flynn

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose: To evaluate the visual outcomes, choroidal neovascular complex status, and adverse events in patients with visually significant cataract and neovascular age-related macular degeneration (AMD) who had cataract surgery. Setting: Private practices, Beverly Hills, California, and New London, Connecticut, USA. Design: Case series. Methods: Data were abstracted from the medical records of patients with neovascular AMD treated by anti-vascular endothelial growth factor (anti-VEGF) therapy who had cataract surgery. The main outcome measures were Snellen corrected distance visual acuity (CDVA), perioperative adverse events, and status of the choroidal neovascular complex. Results: The study enrolled 30 eyes of 28 patients. The CDVA was 20/40 or better in 10% of eyes preoperatively and 40% postoperatively; 20/50 to 20/100 in 53% and 33%, respectively; and 20/200 or worse in 37% and 27%, respectively. The change in CDVA from preoperatively to postoperatively was statistically significant, with a mean change of 0.22 logMAR ± 0.27 (SD) at 2 months (P<.0001), 0.22 ± 0.36 logMAR at 6 months (P=.001), and 0.17 ± 0.54 logMAR at the last follow-up (P=.01). Patients received a mean of 0.32 injections per month postoperatively compared with 0.49 injections per month preoperatively. Perioperative macular adverse events did not occur in any eye. Conclusions: With regular evaluations and appropriate treatment with anti-VEGF agents, cataract surgery did not appear to be associated with an increased incidence of perioperative complications or macular adverse events. Financial Disclosures: Dr. Tabandeh is a consultant/advisor to Alcon and Allergan. Dr. Boyer is a consultant/advisor to Alcon, Allergan, Genentech, Regeneron, Novartis, Pfizer, and Optos and has received lecture fees from Allergan, Alcon, Genentech, and Pfizer. No other author has a financial or proprietary interest in any material or method mentioned.

Original languageEnglish
Pages (from-to)677-682
Number of pages6
JournalJournal of Cataract and Refractive Surgery
Volume38
Issue number4
DOIs
StatePublished - Apr 1 2012

Fingerprint

Macular Degeneration
Cataract
Vascular Endothelial Growth Factor A
Visual Acuity
Consultants
Injections
Fees and Charges
Private Practice
Disclosure
Therapeutics
Medical Records
Outcome Assessment (Health Care)
Incidence

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Surgery

Cite this

Outcomes of cataract surgery in patients with neovascular age-related macular degeneration in the era of anti-vascular endothelial growth factor therapy. / Tabandeh, Homayoun; Chaudhry, Nauman A.; Boyer, David S.; Kon-Jara, Veronica A.; Flynn, Harry W.

In: Journal of Cataract and Refractive Surgery, Vol. 38, No. 4, 01.04.2012, p. 677-682.

Research output: Contribution to journalArticle

@article{1ff2facf98dc41d0bce9b560d6b9e5be,
title = "Outcomes of cataract surgery in patients with neovascular age-related macular degeneration in the era of anti-vascular endothelial growth factor therapy",
abstract = "Purpose: To evaluate the visual outcomes, choroidal neovascular complex status, and adverse events in patients with visually significant cataract and neovascular age-related macular degeneration (AMD) who had cataract surgery. Setting: Private practices, Beverly Hills, California, and New London, Connecticut, USA. Design: Case series. Methods: Data were abstracted from the medical records of patients with neovascular AMD treated by anti-vascular endothelial growth factor (anti-VEGF) therapy who had cataract surgery. The main outcome measures were Snellen corrected distance visual acuity (CDVA), perioperative adverse events, and status of the choroidal neovascular complex. Results: The study enrolled 30 eyes of 28 patients. The CDVA was 20/40 or better in 10{\%} of eyes preoperatively and 40{\%} postoperatively; 20/50 to 20/100 in 53{\%} and 33{\%}, respectively; and 20/200 or worse in 37{\%} and 27{\%}, respectively. The change in CDVA from preoperatively to postoperatively was statistically significant, with a mean change of 0.22 logMAR ± 0.27 (SD) at 2 months (P<.0001), 0.22 ± 0.36 logMAR at 6 months (P=.001), and 0.17 ± 0.54 logMAR at the last follow-up (P=.01). Patients received a mean of 0.32 injections per month postoperatively compared with 0.49 injections per month preoperatively. Perioperative macular adverse events did not occur in any eye. Conclusions: With regular evaluations and appropriate treatment with anti-VEGF agents, cataract surgery did not appear to be associated with an increased incidence of perioperative complications or macular adverse events. Financial Disclosures: Dr. Tabandeh is a consultant/advisor to Alcon and Allergan. Dr. Boyer is a consultant/advisor to Alcon, Allergan, Genentech, Regeneron, Novartis, Pfizer, and Optos and has received lecture fees from Allergan, Alcon, Genentech, and Pfizer. No other author has a financial or proprietary interest in any material or method mentioned.",
author = "Homayoun Tabandeh and Chaudhry, {Nauman A.} and Boyer, {David S.} and Kon-Jara, {Veronica A.} and Flynn, {Harry W}",
year = "2012",
month = "4",
day = "1",
doi = "10.1016/j.jcrs.2011.10.036",
language = "English",
volume = "38",
pages = "677--682",
journal = "Journal of Cataract and Refractive Surgery",
issn = "0886-3350",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Outcomes of cataract surgery in patients with neovascular age-related macular degeneration in the era of anti-vascular endothelial growth factor therapy

AU - Tabandeh, Homayoun

AU - Chaudhry, Nauman A.

AU - Boyer, David S.

AU - Kon-Jara, Veronica A.

AU - Flynn, Harry W

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Purpose: To evaluate the visual outcomes, choroidal neovascular complex status, and adverse events in patients with visually significant cataract and neovascular age-related macular degeneration (AMD) who had cataract surgery. Setting: Private practices, Beverly Hills, California, and New London, Connecticut, USA. Design: Case series. Methods: Data were abstracted from the medical records of patients with neovascular AMD treated by anti-vascular endothelial growth factor (anti-VEGF) therapy who had cataract surgery. The main outcome measures were Snellen corrected distance visual acuity (CDVA), perioperative adverse events, and status of the choroidal neovascular complex. Results: The study enrolled 30 eyes of 28 patients. The CDVA was 20/40 or better in 10% of eyes preoperatively and 40% postoperatively; 20/50 to 20/100 in 53% and 33%, respectively; and 20/200 or worse in 37% and 27%, respectively. The change in CDVA from preoperatively to postoperatively was statistically significant, with a mean change of 0.22 logMAR ± 0.27 (SD) at 2 months (P<.0001), 0.22 ± 0.36 logMAR at 6 months (P=.001), and 0.17 ± 0.54 logMAR at the last follow-up (P=.01). Patients received a mean of 0.32 injections per month postoperatively compared with 0.49 injections per month preoperatively. Perioperative macular adverse events did not occur in any eye. Conclusions: With regular evaluations and appropriate treatment with anti-VEGF agents, cataract surgery did not appear to be associated with an increased incidence of perioperative complications or macular adverse events. Financial Disclosures: Dr. Tabandeh is a consultant/advisor to Alcon and Allergan. Dr. Boyer is a consultant/advisor to Alcon, Allergan, Genentech, Regeneron, Novartis, Pfizer, and Optos and has received lecture fees from Allergan, Alcon, Genentech, and Pfizer. No other author has a financial or proprietary interest in any material or method mentioned.

AB - Purpose: To evaluate the visual outcomes, choroidal neovascular complex status, and adverse events in patients with visually significant cataract and neovascular age-related macular degeneration (AMD) who had cataract surgery. Setting: Private practices, Beverly Hills, California, and New London, Connecticut, USA. Design: Case series. Methods: Data were abstracted from the medical records of patients with neovascular AMD treated by anti-vascular endothelial growth factor (anti-VEGF) therapy who had cataract surgery. The main outcome measures were Snellen corrected distance visual acuity (CDVA), perioperative adverse events, and status of the choroidal neovascular complex. Results: The study enrolled 30 eyes of 28 patients. The CDVA was 20/40 or better in 10% of eyes preoperatively and 40% postoperatively; 20/50 to 20/100 in 53% and 33%, respectively; and 20/200 or worse in 37% and 27%, respectively. The change in CDVA from preoperatively to postoperatively was statistically significant, with a mean change of 0.22 logMAR ± 0.27 (SD) at 2 months (P<.0001), 0.22 ± 0.36 logMAR at 6 months (P=.001), and 0.17 ± 0.54 logMAR at the last follow-up (P=.01). Patients received a mean of 0.32 injections per month postoperatively compared with 0.49 injections per month preoperatively. Perioperative macular adverse events did not occur in any eye. Conclusions: With regular evaluations and appropriate treatment with anti-VEGF agents, cataract surgery did not appear to be associated with an increased incidence of perioperative complications or macular adverse events. Financial Disclosures: Dr. Tabandeh is a consultant/advisor to Alcon and Allergan. Dr. Boyer is a consultant/advisor to Alcon, Allergan, Genentech, Regeneron, Novartis, Pfizer, and Optos and has received lecture fees from Allergan, Alcon, Genentech, and Pfizer. No other author has a financial or proprietary interest in any material or method mentioned.

UR - http://www.scopus.com/inward/record.url?scp=84858865646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858865646&partnerID=8YFLogxK

U2 - 10.1016/j.jcrs.2011.10.036

DO - 10.1016/j.jcrs.2011.10.036

M3 - Article

C2 - 22284725

AN - SCOPUS:84858865646

VL - 38

SP - 677

EP - 682

JO - Journal of Cataract and Refractive Surgery

JF - Journal of Cataract and Refractive Surgery

SN - 0886-3350

IS - 4

ER -